P

Inventor

KEHRY MARILYN

US13 patents
⚠️ This page may combine multiple inventors who share the name “KEHRY MARILYN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ANAPTYSBIO INC

7 patents
US9815897B2Nov 14, 2017

Antibodies directed against programmed death-1 (PD-1)

ANAPTYSBIO INC24 citations93
US10738117B2Aug 11, 2020

Antibodies directed against programmed death-1 (PD-1)

ANAPTYSBIO INC10 citations83
US10508149B2Dec 17, 2019

Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)

ANAPTYSBIO INC7 citations80
US11352427B2Jun 7, 2022

Antibodies directed against T Cell immunoglobulin and mucin protein 3 (TIM-3)

ANAPTYSBIO INC2 citations69
US11155624B2Oct 26, 2021

Antibodies directed against programmed death-1 (PD-1)

ANAPTYSBIO INC4 citations69
US11753472B2Sep 12, 2023

Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3)

ANAPTYSBIO INC2 citations65
US10836824B2Nov 17, 2020

Antibodies directed against lymphocyte activation gene 3 (LAG-3)

ANAPTYSBIO INC1 citations59

MOMENTA PHARMACEUTICALS INC

3 patents
US10676526B2Jun 9, 2020

FcRn antibodies and methods of use thereof

MOMENTA PHARMACEUTICALS INC9 citations82
US11345751B2May 31, 2022

FcRn antibodies and methods of use thereof

MOMENTA PHARMACEUTICALS INC4 citations70
US11732047B2Aug 22, 2023

FcRn antibodies and methods of use thereof

MOMENTA PHARMACEUTICALS INC1 citations61

BOEHRINGER INGELHEIM PHARMA

2 patents
US5817516AOct 6, 1998

Methods for proliferating and differentiating B cells with high density membrane CD40 ligand

BOEHRINGER INGELHEIM PHARMA31 citations88
US6297052B1Oct 2, 2001

B cell culture system comprising high density membrane bound CD40 ligand

BOEHRINGER INGELHEIM PHARMA7 citations69

CELGENE CORP

1 patent
US10428145B2Oct 1, 2019

PD-1 binding proteins and methods of use thereof

CELGENE CORP10 citations77